Molecular imaging in drug discovery and development
10.1038/nrd1007
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Drug Discovery (297)
Authors 2
  1. Markus Rudin (first)
  2. Ralph Weissleder (additional)
References 79 Referenced 665
  1. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nature Rev. Cancer 2, 11–18 (2002). Review of in vivo mouse imaging technologies. (10.1038/nrc701) / Nature Rev. Cancer by R Weissleder (2002)
  2. Weissleder, R. & Ntziachristos, V. Shedding light onto live molecular targets. Nature Med. 9, 123–128 (2003). This manuscript reviews emerging novel optical in vivo imaging technologies. (10.1038/nm0103-123) / Nature Med. by R Weissleder (2003)
  3. Rudin, M. et al. In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. NMR Biomed. 12, 69–97 (1999). Review of MR technologies in drug development. (10.1002/(SICI)1099-1492(199904)12:2<69::AID-NBM548>3.0.CO;2-D) / NMR Biomed. by M Rudin (1999)
  4. Beckmann, N., Mueggler, T., Allegrini, P. R., Laurent, D. & Rudin, M. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat. Rec. 265, 85–100 (2001). (10.1002/ar.1059) / Anat. Rec. by N Beckmann (2001)
  5. Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nature Rev. Cancer 2, 266–276 (2002). (10.1038/nrc778) / Nature Rev. Cancer by RK Jain (2002)
  6. Phelps, M. E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl Acad. Sci. USA 97, 9226–9233 (2000). Review of PET imaging applications. (10.1073/pnas.97.16.9226) / Proc. Natl Acad. Sci. USA by ME Phelps (2000)
  7. Fischman, A. J., Alpert, N. M. & Rubin, R. H. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin. Pharmacokinet. 41, 581–602 (2002). Review of the role of PET in the study of drug pharmacokinetics. (10.2165/00003088-200241080-00003) / Clin. Pharmacokinet. by AJ Fischman (2002)
  8. Reese, T., Bochelen, D., Sauter, A., Beckmann, N. & Rudin, M. Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. NMR Biomed. 12, 189–196 (1999). (10.1002/(SICI)1099-1492(199906)12:4<189::AID-NBM557>3.0.CO;2-O) / NMR Biomed. by T Reese (1999)
  9. Villringer, A. et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn. Reson. Med. 6, 164–174 (1988). (10.1002/mrm.1910060205) / Magn. Reson. Med. by A Villringer (1988)
  10. Roussel, S. A., van Bruggen, N., King, M. D. & Gadian, D. G. Identification of collaterally perfused areas following focal cerebral ischemia in the rat by comparison of gradient echo and diffusion-weighted MRI. J. Cereb. Blood Flow Metab. 15, 578–586 (1995). (10.1038/jcbfm.1995.71) / J. Cereb. Blood Flow Metab. by SA Roussel (1995)
  11. Moseley, M., Wendland, M. & Kucharczyk, J. Magnetic resonance imaging of diffusion and perfusion. Top. Magn. Reson. Imaging 3, 50–67 (1991). / Top. Magn. Reson. Imaging by M Moseley (1991)
  12. Sauter, A. & Rudin, M. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke 17, 1228–1234 (1986). (10.1161/01.STR.17.6.1228) / Stroke by A Sauter (1986)
  13. Rausch, M., Baumann, D., Neubacher, U. & Rudin, M. In vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO. NMR Biomed. 15, 278–283 (2002). (10.1002/nbm.770) / NMR Biomed. by M Rausch (2002)
  14. Sauter, A. et al. Recovery of function in cytoprotected cerebral cortex in rat stroke model assessed by functional MRI. Magn. Reson. Med. 47, 759–765 (2002). (10.1002/mrm.10123) / Magn. Reson. Med. by A Sauter (2002)
  15. Cristofanilli, M., Charnsangavej, C. & Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Rev. Drug Discov. 1, 415–426 (2002). (10.1038/nrd819) / Nature Rev. Drug Discov. by M Cristofanilli (2002)
  16. Tatum, J. L. & Hoffman, J. M. Role of imaging in clinical trials of antiangiogenesis therapy in oncology. Acad. Radiol. 7, 798–799 (2000). (10.1016/S1076-6332(00)80628-5) / Acad. Radiol. by JL Tatum (2000)
  17. Bhujwalla, Z. M. et al. The physiological environment in cancer vascularization, invasion and metastasis. Novartis Found Symp. 240, 23–38; discussion 38-45, 152-153, (2001). (10.1002/0470868716.ch3) / Novartis Found Symp. by ZM Bhujwalla (2001)
  18. Lewin, M. et al. In vivo assessment of vascular endothelial growth factor-induced angiogenesis. Int. J. Cancer 83, 798–802 (1999). (10.1002/(SICI)1097-0215(19991210)83:6<798::AID-IJC16>3.0.CO;2-W) / Int. J. Cancer by M Lewin (1999)
  19. Petrovsky, A., Weissleder, W., Shalinsky, D., Hu-Lowe, D. & Bogdanov, A. Non-invasive magnetic resonance imaging (MRI) of vascular parameters affected by VEGF–receptor tyrosine kinase inhibition in a human xenograft model. Proc. Am. Assoc. Cancer Res. 43, 1081 (2002). / Proc. Am. Assoc. Cancer Res. by A Petrovsky (2002)
  20. Peterfy, C. G. Magnetic resonance imaging of rheumatoid arthritis: the evolution of clinical applications through clinical trials. Semin. Arthritis Rheum. 30, 375–396 (2001). (10.1053/sarh.2001.22497) / Semin. Arthritis Rheum. by CG Peterfy (2001)
  21. McConnell, M. V. et al. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 19, 1956–1959 (1999). (10.1161/01.ATV.19.8.1956) / Arterioscler. Thromb. Vasc. Biol. by MV McConnell (1999)
  22. Chinnaiyan, A. M. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl Acad. Sci. USA 97, 1754–1759 (2000). (10.1073/pnas.030545097) / Proc. Natl Acad. Sci. USA by AM Chinnaiyan (2000)
  23. Jennings, D. et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 4, 255–262 (2002). (10.1038/sj.neo.7900225) / Neoplasia by D Jennings (2002)
  24. Evelhoch, J. L. et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2, 152–165 (2000). (10.1038/sj.neo.7900078) / Neoplasia by JL Evelhoch (2000)
  25. Cherry, S. R. Fundamentals of positron emission tomography and applications in preclinical drug development. J. Clin. Pharmacol. 41, 482–491 (2001). (10.1177/00912700122010357) / J. Clin. Pharmacol. by SR Cherry (2001)
  26. Del Guerra, A. & Belcari, N. Advances in animal PET scanners. Q. J. Nucl. Med. 46, 35–47 (2002). / Q. J. Nucl. Med. by A Del Guerra (2002)
  27. Green, L. A. et al. Noninvasive methods for quantitating blood time–activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J. Nucl. Med. 39, 729–734 (1998). / J. Nucl. Med. by LA Green (1998)
  28. Chatziioannou, A., Tai, Y. C., Doshi, N. & Cherry, S. R. Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. Phys. Med. Biol. 46, 2899–2910 (2001). (10.1088/0031-9155/46/11/310) / Phys. Med. Biol. by A Chatziioannou (2001)
  29. Brady, F. et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr. Pharm. Des. 7, 1863–1892 (2001). (10.2174/1381612013396907) / Curr. Pharm. Des. by F Brady (2001)
  30. Halldin, C., Gulyas, B. & Farde, L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr. Pharm. Des. 7, 1907–1929 (2001). Review of PET in the development of drugs for mental health disorders. (10.2174/1381612013396871) / Curr. Pharm. Des. by C Halldin (2001)
  31. Fischman, A. J. et al. Pharmacokinetics of 18F fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. Antimicrob. Agents Chemother. 40, 659–664 (1996). (10.1128/AAC.40.3.659) / Antimicrob. Agents Chemother. by AJ Fischman (1996)
  32. Fischman, A. J. et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J. Pharmacol. Exp. Ther. 279, 939–947 (1996). / J. Pharmacol. Exp. Ther. by AJ Fischman (1996)
  33. Aboagye, E. O. et al. Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br. J. Cancer 86, 1052–1056 (2002). (10.1038/sj.bjc.6600212) / Br. J. Cancer by EO Aboagye (2002)
  34. Gibson, R. E. et al. Non-invasive radiotracer imaging as a tool for drug development. Curr. Pharm. Des. 6, 973–989 (2000). (10.2174/1381612003399987) / Curr. Pharm. Des. by RE Gibson (2000)
  35. Fischman, A. J. et al. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob. Agents Chemother. 37, 1270–1277 (1993). (10.1128/AAC.37.6.1270) / Antimicrob. Agents Chemother. by AJ Fischman (1993)
  36. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493–502 (2002). (10.1038/nrd839) / Nature Rev. Drug Discov. by R Capdeville (2002)
  37. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002). (10.1126/science.1067100) / Science by LM Coussens (2002)
  38. Warner, R. R. & O'Dorisio T. M. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin. Nucl. Med. 32, 79–83 (2002). (10.1053/snuc.2002.31020) / Semin. Nucl. Med. by RR Warner (2002)
  39. Becker, A. et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nature Biotechnol. 19, 327–331 (2001). (10.1038/86707) / Nature Biotechnol. by A Becker (2001)
  40. Bugaj, J. E., Achilefu, S., Dorshow, R. B. & Rajagopalan, R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye–peptide conjugate platform. J. Biomed. Opt. 6, 122–133 (2001). (10.1117/1.1352748) / J. Biomed. Opt. by JE Bugaj (2001)
  41. Tung, C. H., Lin, Y., Moon, W. K. & Weissleder, R. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochem 3, 784–786 (2002). (10.1002/1439-7633(20020802)3:8<784::AID-CBIC784>3.0.CO;2-X) / Chembiochem by CH Tung (2002)
  42. Weissleder, R. et al. In vivo magnetic resonance imaging of transgene expression. Nature Med. 6, 351–355 (2000). (10.1038/73219) / Nature Med. by R Weissleder (2000)
  43. Hogemann, D., Ntziachristos, V., Josephson, L. & Weissleder, R. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug. Chem. 13, 116–121 (2002). (10.1021/bc015549h) / Bioconjug. Chem. by D Hogemann (2002)
  44. Sipkins, D. A. et al. Detection of tumor angiogenesis in vivo by αVβ3-targeted magnetic resonance imaging. Nature Med. 4, 623–626 (1998). (10.1038/nm0598-623) / Nature Med. by DA Sipkins (1998)
  45. Burns, H. D. et al. Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. Curr. Opin. Chem. Biol. 3, 388–394 (1999). (10.1016/S1367-5931(99)80059-3) / Curr. Opin. Chem. Biol. by HD Burns (1999)
  46. Hartvig, P., Bergstrom, M., Antoni, G. & Langstrom, B. Positron emission tomography and brain monoamine neurotransmission — entries for study of drug interactions. Curr. Pharm. Des. 8, 1417–1434 (2002). (10.2174/1381612023394458) / Curr. Pharm. Des. by P Hartvig (2002)
  47. Fowler, J. S. et al. Positron emission tomography studies of dopamine-enhancing drugs. J. Clin. Pharmacol. (Suppl.) 13–16 (1999). (10.1002/j.1552-4604.1999.tb05932.x)
  48. Hietala, J. Ligand–receptor interactions as studied by PET: implications for drug development. Ann. Med. 31, 438–443 (1999). (10.3109/07853899908998802) / Ann. Med. by J Hietala (1999)
  49. Laakso, A. & Hietala, J. PET studies of brain monoamine transporters. Curr. Pharm. Des. 6, 1611–1623 (2000). (10.2174/1381612003398799) / Curr. Pharm. Des. by A Laakso (2000)
  50. Passchier, J. & van Waarde, A. Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur. J. Nucl. Med. 28, 113–129 (2001). (10.1007/s002590000394) / Eur. J. Nucl. Med. by J Passchier (2001)
  51. Pilowsky, L. S. Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl. Med. Commun. 22, 829–833 (2001). (10.1097/00006231-200107000-00016) / Nucl. Med. Commun. by LS Pilowsky (2001)
  52. Volkow, N. D., Ding, Y. S., Fowler, J. S. & Gatley, S. J. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol. Psychiatry 49, 211–220 (2001). (10.1016/S0006-3223(00)01112-4) / Biol. Psychiatry by ND Volkow (2001)
  53. Waarde, A. Measuring receptor occupancy with PET. Curr. Pharm. Des. 6, 1593–1610 (2000). (10.2174/1381612003398951) / Curr. Pharm. Des. by A Waarde (2000)
  54. Martinez, D. et al. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with 11C WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24, 209–229 (2001). (10.1016/S0893-133X(00)00187-1) / Neuropsychopharmacology by D Martinez (2001)
  55. Louie, A. Y. et al. In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnol. 18, 321–325 (2000). (10.1038/73780) / Nature Biotechnol. by AY Louie (2000)
  56. Perez, J. M., Josephson, L., O'Loughlin, T., Hogemann, D. & Weissleder, R. Magnetic relaxation switches capable of sensing molecular interactions. Nature Biotechnol. 20, 816–820 (2002). (10.1038/nbt720) / Nature Biotechnol. by JM Perez (2002)
  57. Bremer, C., Tung, C. H. & Weissleder, R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Med. 7, 743–748 (2001). (10.1038/89126) / Nature Med. by C Bremer (2001)
  58. Mahmood, U., Tung, C. H., Tang, Y. & Weissleder, R. Feasibility of in vivo multichannel optical imaging of gene expression: experimental study in mice. Radiology 224, 446–451 (2002). (10.1148/radiol.2242011589) / Radiology by U Mahmood (2002)
  59. Lewin, M. et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nature Biotechnol. 18, 410–414 (2000). (10.1038/74464) / Nature Biotechnol. by M Lewin (2000)
  60. Sharma, V., Luker, G. D. & Piwnica-Worms, D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J. Magn. Reson. Imaging 16, 336–351 (2002). (10.1002/jmri.10182) / J. Magn. Reson. Imaging by V Sharma (2002)
  61. Zhao, M., Kircher, M. F., Josephson, L. & Weissleder, R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 13, 840–844 (2002). (10.1021/bc0255236) / Bioconjug. Chem. by M Zhao (2002)
  62. Tjuvajev, J. G. et al. Imaging the expression of transfected genes in vivo. Cancer Res. 55, 6126–6132 (1995). / Cancer Res. by JG Tjuvajev (1995)
  63. Gambhir, S. S. et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc. Natl Acad. Sci. USA 96, 2333–2338 (1999). (10.1073/pnas.96.5.2333) / Proc. Natl Acad. Sci. USA by SS Gambhir (1999)
  64. Li, X., Zhang, S., Zhao, P., Kovacs, Z. & Sherry, A. D. Synthesis and NMR studies of new DOTP-like lanthanide(III) complexes containing a hydrophobic substituent on one phosphonate side arm. Inorg. Chem. 40, 6572–6579 (2001). (10.1021/ic010291s) / Inorg. Chem. by X Li (2001)
  65. Bornhop, D. J. et al. Fluorescent tissue site-selective lanthanide chelate, Tb-PCTMB for enhanced imaging of cancer. Anal. Chem. 71, 2607–2615 (1999). (10.1021/ac981208u) / Anal. Chem. by DJ Bornhop (1999)
  66. Tromberg, B. J. et al. Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. Neoplasia 2, 26–40 (2000). (10.1038/sj.neo.7900082) / Neoplasia by BJ Tromberg (2000)
  67. Chance, B. Near-infrared (NIR) optical spectroscopy characterizes breast tissue hormonal and age status. Acad. Radiol. 8, 209–210 (2001). (10.1016/S1076-6332(03)80528-7) / Acad. Radiol. by B Chance (2001)
  68. Hanlon, E. B. et al. Prospects for in vivo Raman spectroscopy. Phys. Med. Biol. 45, R1–R59 (2000). (10.1088/0031-9155/45/2/201) / Phys. Med. Biol. by EB Hanlon (2000)
  69. Brown, E. B. et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nature Med. 7, 864–868 (2001). (10.1038/89997) / Nature Med. by EB Brown (2001)
  70. Ntziachristos, V., Tung, C. H., Bremer, C. & Weissleder, R. Fluorescence molecular tomography resolves protease activity in vivo. Nature Med. 8, 757–760 (2002). (10.1038/nm729) / Nature Med. by V Ntziachristos (2002)
  71. Marten, K. et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122, 406–414 (2002). (10.1053/gast.2002.30990) / Gastroenterology by K Marten (2002)
  72. Ito, S. et al. Detection of human gastric cancer in resected specimens using a novel infrared fluorescent anti-human carcinoembryonic antigen antibody with an infrared fluorescence endoscope in vitro. Endoscopy 33, 849–853 (2001). (10.1055/s-2001-17328) / Endoscopy by S Ito (2001)
  73. Zonios, G., Bykowski, J. & Kollias, N. Skin melanin, hemoglobin, and light scattering properties can be quantitatively assessed in vivo using diffuse reflectance spectroscopy. J. Invest. Dermatol. 117, 1452–1457 (2001). (10.1046/j.0022-202x.2001.01577.x) / J. Invest. Dermatol. by G Zonios (2001)
  74. Kuroiwa, T., Kajimoto, Y. & Ohta, T. Development and clinical application of near-infrared surgical microscope: preliminary report. Minim. Invasive. Neurosurg. 44, 240–242 (2001). (10.1055/s-2001-19929) / Minim. Invasive. Neurosurg. by T Kuroiwa (2001)
  75. Ntziachristos, V., Ripoll, J. & Weissleder, R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Opt. Lett. 27, 333–335 (2002). (10.1364/OL.27.000333) / Opt. Lett. by V Ntziachristos (2002)
  76. Contag, C. H. et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochemistry & Photobiology 4, 523–531 (1997). (10.1111/j.1751-1097.1997.tb03184.x) / Photochemistry & Photobiology by CH Contag (1997)
  77. Hastings, J. W. Chemistries and colors of bioluminescent reactions: a review. Gene 173, 5–11 (1996). (10.1016/0378-1119(95)00676-1) / Gene by JW Hastings (1996)
  78. Bhaumik, S. & Gambhir, S. S. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc. Natl Acad. Sci. USA 99, 377–382 (2002). (10.1073/pnas.012611099) / Proc. Natl Acad. Sci. USA by S Bhaumik (2002)
  79. Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov. 1, 153–161 (2002). (10.1038/nrd728) / Nature Rev. Drug Discov. by JK Nicholson (2002)
Dates
Type When
Created 22 years, 7 months ago (Jan. 31, 2003, 11:15 a.m.)
Deposited 1 year, 7 months ago (Jan. 8, 2024, 5:20 p.m.)
Indexed 1 week, 1 day ago (Aug. 26, 2025, 3:03 a.m.)
Issued 22 years, 7 months ago (Feb. 1, 2003)
Published 22 years, 7 months ago (Feb. 1, 2003)
Published Print 22 years, 7 months ago (Feb. 1, 2003)
Funders 0

None

@article{Rudin_2003, title={Molecular imaging in drug discovery and development}, volume={2}, ISSN={1474-1784}, url={http://dx.doi.org/10.1038/nrd1007}, DOI={10.1038/nrd1007}, number={2}, journal={Nature Reviews Drug Discovery}, publisher={Springer Science and Business Media LLC}, author={Rudin, Markus and Weissleder, Ralph}, year={2003}, month=feb, pages={123–131} }